Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
SJ Thomas, ED Moreira Jr, N Kitchin… - … England Journal of …, 2021 - Mass Medical Soc
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA
vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly
efficacious against coronavirus disease 2019 (Covid-19) and is currently approved,
conditionally approved, or authorized for emergency use worldwide. At the time of initial
authorization, data beyond 2 months after vaccination were unavailable. Methods In an …
vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly
efficacious against coronavirus disease 2019 (Covid-19) and is currently approved,
conditionally approved, or authorized for emergency use worldwide. At the time of initial
authorization, data beyond 2 months after vaccination were unavailable. Methods In an …